Neuralstem, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. The filing identifies the registrant as Neuralstem, Inc., not Palisade Bio, Inc.; it is an annual report rather than a quarterly filing. Neuralstem is a clinical-stage biopharmaceutical company developing human neural stem-cell therapies and small-molecule compounds for central nervous system diseases. Its principal programs were NSI-189 and NSI-566.
Financial performance and position
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $260,000 | $16,246 | Increase of $243,754 |
| Operating expenses | $13.57 million | $20.65 million | Decrease of 34% |
| Operating loss | $13.31 million | $20.64 million | Improved by $7.33 million |
| Net loss | $15.67 million | $21.07 million | Improved by $5.41 million |
| Net loss per share | $1.20 | $2.53 | Improved; share counts increased |
| Net cash used in operations | $13.42 million | $15.62 million | Use decreased by 14% |
| Cash, cash equivalents and short-term investments | $11.67 million | $20.19 million | Decrease of 42% |
| Stockholders’ equity | $8.52 million | $11.33 million | Decrease of 25% |
Revenue did not come from commercial product sales. The filing describes $10,000 of recurring intellectual-property licensing revenue and $250,000 of milestone-based revenue related to settlement of a prior patent infringement case. No product candidate had regulatory approval or commercial sales.
Research and development expense declined 38% to $8.10 million, primarily because of lower personnel, facility and other costs, completion of the NSI-189 Phase 2 trial, and lower share-based compensation. General and administrative expense declined 27% to $5.47 million following restructuring and cost-reduction efforts. Operating margin was approximately negative 5,118% in 2017, reflecting minimal revenue relative to the company’s development costs.
Other expense increased to $2.36 million from $438,000. The 2017 amount included a $1.47 million non-cash loss from changes in the fair value of liability-classified warrants, $564,000 of warrant inducement expense, $243,000 of expenses related to warrants issued in the August financing, and $159,000 of interest expense.
The company paid off its long-term debt in April 2017. At year-end, the balance sheet reported no current portion of long-term debt, but included $3.85 million of warrant liabilities. Total liabilities were $5.37 million, compared with $11.27 million in 2016.
Cash flow, financing and liquidity
- Operating activities consumed $13.42 million of cash.
- Investing activities used $94,000, primarily for patent costs and property and equipment.
- Financing activities provided $4.99 million, including $5.41 million of net proceeds from the August 2017 offering and $3.23 million from warrant exercises, partly offset by $3.77 million of long-term debt repayments.
- In August 2017, the company sold 3.0 million common shares and 2.25 million warrants for gross proceeds of $6.0 million and net proceeds of approximately $5.4 million.
- Management expected existing cash and investments to fund operations into the first quarter of 2019 under current spending plans, but stated that additional capital would be required.
- The auditors and management disclosed substantial doubt about the company’s ability to continue as a going concern. The company had no committed future financing and could be required to delay or terminate programs, curtail operations, cease operations or seek bankruptcy protection if financing is unavailable.
Material changes versus 2016
- Net loss and operating loss improved as the company reduced development and administrative spending.
- Cash resources fell substantially because operating cash consumption and debt repayment exceeded financing inflows.
- Revenue increased primarily because of a one-time $250,000 patent settlement milestone, not recurring product revenue.
- Share count increased from 11.0 million to 15.2 million shares outstanding, principally from financing transactions and warrant exercises, creating dilution risk.
- The company completed a 1-for-13 reverse stock split effective January 2017; historical share and per-share figures were adjusted accordingly.
- The long-term debt was fully repaid, while warrant liabilities remained material and subject to recurring fair-value changes through earnings.
Clinical, outlook and unusual items
- NSI-189’s exploratory Phase 2 trial in major depressive disorder failed to meet its primary endpoint of statistically significant improvement in MADRS depression scores versus placebo. Management highlighted statistically significant results on certain secondary patient-reported and cognitive measures, but the negative primary endpoint materially increased development and financing risk.
- NSI-566 stem-cell programs continued in ALS, ischemic stroke and chronic spinal cord injury. The ALS Phase 2 study met reported safety endpoints, while the stroke and spinal-cord-injury studies remained early-stage and were not powered to establish efficacy.
- The company received an approximately $1 million, two-year NIH SBIR grant for preclinical evaluation of NSI-189 in diabetic neuropathy, subject to conditions. Approximately $41,000 of grant reimbursements was recorded as an offset to research and development expense in 2017.
- The company recognized an approximately $92,000 loss for ceasing use of its San Diego research facility and remained responsible for lease payments while exploring subleasing opportunities.
- Management expected continued losses for at least the next several years and planned to seek additional equity or debt financing, grants, collaborations and licensing transactions.
- Key risks include clinical failure, regulatory delay or denial, dependence on third-party manufacturers and clinical organizations, patent challenges, limited personnel, competition, dilution from future securities issuance, and potential Nasdaq delisting.
Most important facts to verify
- Confirm the issuer identity: the supplied filing is for Neuralstem, Inc. and trades under the symbol CUR, not Palisade Bio, Inc.
- Verify the going-concern disclosure and the company’s actual cash runway after December 31, 2017.
- Review subsequent financing, restructuring, clinical-development and asset-sale activity after the filing date.
- Assess the implications of the failed NSI-189 primary endpoint and whether any follow-on development or licensing activity occurred.
- Reconcile the $260,000 reported revenue with the recurring $10,000 licensing revenue and the one-time $250,000 patent settlement milestone.
- Review outstanding warrants, preferred-stock conversion rights and other equity-linked instruments for potential dilution and cash obligations.
- Confirm the status of the company’s Nasdaq listing, patent portfolio and third-party manufacturing arrangements.